Literature DB >> 33314936

Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives.

Wei Zheng1,2, Zhen Wang1, Xiangrui Jiang1, Qingjie Zhao1, Jingshan Shen1,2.   

Abstract

Pulmonary arterial hypertension (PAH) is a devastating disease that can lead to right ventricular failure and premature death. Although approved drugs have been shown to be safe and effective, PAH remains a severe clinical condition, and the long-term survival of patients with PAH is still suboptimal. Thus, potential therapeutic targets and new agents to treat PAH are urgently needed. In recent years, a variety of related pathways and potential therapeutic targets have been found, which brings new hope for PAH therapy. In this perspective, not only are the marketed drugs used to treat PAH summarized but also the recently developed novel pharmaceutical therapies currently in clinical trials are discussed. Furthermore, the advances in natural products as potential treatment for PAH are also updated.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33314936     DOI: 10.1021/acs.jmedchem.0c01093

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

Review 1.  Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension.

Authors:  Adrija Hajra; Israel Safiriyu; Prasanth Balasubramanian; Rahul Gupta; Selia Chowdhury; Abhishek J Prasad; Akshay Kumar; Deepak Kumar; Baseer Khan; Roberta S F Bilberry; Ankit Sarkar; Paras Malik; Wilbert S Aronow
Journal:  Curr Probl Cardiol       Date:  2022-04-29       Impact factor: 16.464

Review 2.  New Halogen-Containing Drugs Approved by FDA in 2021: An Overview on Their Syntheses and Pharmaceutical Use.

Authors:  Davide Benedetto Tiz; Luana Bagnoli; Ornelio Rosati; Francesca Marini; Luca Sancineto; Claudio Santi
Journal:  Molecules       Date:  2022-03-02       Impact factor: 4.411

3.  Polydatin Glycosides Improve Monocrotaline-Induced Pulmonary Hypertension Injury by Inhibiting Endothelial-To-Mesenchymal Transition.

Authors:  Xing Chen; Yao He; Zhijie Yu; Jianli Zuo; Yan Huang; Yi Ruan; Xiaoyuan Zheng; Yu Ma
Journal:  Front Pharmacol       Date:  2022-03-18       Impact factor: 5.810

4.  A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects.

Authors:  Hongjie Qian; Qian Chen; Liyu Liang; Yang Zou; Huahua Pu; Liang Xin; Rong Song; Tingting Li; Huijuan Zhu; Yu Wang; Guanghui Tian; Jingshan Shen; Hualiang Jiang; Chen Yu; Zhen Wang; Jingying Jia
Journal:  Drug Des Devel Ther       Date:  2021-07-06       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.